drugset
drugset / Trial / NCT03142451

A Study (Study 1) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea

NCT03142451 ↗

Phase 3 Completed 751 enrolled Vyne Therapeutics Inc. Premier Research · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objectives of this study are to determine the efficacy and safety of FMX103 1.5% minocycline foam applied topically once daily for 12 weeks in the treatment of rosacea.

Timeline

Start
2017-06-02
Primary completion
2018-08-31
Completion
2018-09-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Minocycline Small molecule 1.5 % Topical
Subject Minocycline Small molecule 7.5 mg Topical

Indications

rosacea